Literature DB >> 8349579

The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells.

V Ramkumar1, G L Stiles, M A Beaven, H Ali.   

Abstract

Mast cells release the mediators of the immediate hypersensitivity reaction. Adenosine is known to modulate this process, but the receptor responsible for this is not the classical A1 or A2 adenosine receptors. This study was undertaken to determine whether the unique adenosine receptor (AR) previously postulated in a cultured mast cell line (RBL-2H3 cells) is the recently cloned A3AR. The receptors were quantitated by the agonist 125I-labeled APNEA (aminophenylethyladenosine), an A3AR agonist, which yielded Bmax and Kd values of 826 fmol/mg protein and 34 nM, respectively. A variety of adenosine analogs competed for 125I-APNEA binding sites with the following potency series: (R)-phenylisopropyladenosine = 5'-N-ethylcarboxamide adenosine > (S)-phenylisopropyladenosine. 125I-APNEA binding was relatively insensitive to the xanthine amine congener (XAC, 1 microM), a selective antagonist for the A1AR. Functionally, activation of these A3AR stimulated the production of inositol 1,4,5-triphosphate, leading to an increase in the level of intracellular Ca2+. Furthermore, while activation of these receptors alone produced little secretory response in RBL-2H3 cells, it enhanced antigen-induced secretion by 2-2.5-fold. Northern blotting studies using poly(A+) RNA from RBL-2H3 cells detected two transcripts of 2.0 and 3.5 kilobases, which hybridized to an A3AR cDNA but not to the A1 or A2AR cDNA probes. These data indicate that the unique AR that potentiates the secretory response to antigen in RBL-2H3 cells is exclusively the A3AR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349579

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  108 in total

1.  Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release.

Authors:  C I Ezeamuzie; E Philips
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.

Authors:  S Gessi; K Varani; S Merighi; A Morelli; D Ferrari; E Leung; P G Baraldi; G Spalluto; P A Borea
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 3.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

4.  Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.

Authors:  Zhan-Guo Gao; Aishe Chen; Dov Barak; Soo-Kyung Kim; Christa E Müller; Kenneth A Jacobson
Journal:  J Biol Chem       Date:  2002-03-12       Impact factor: 5.157

5.  Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice.

Authors:  Maryam Sharifi Sanjani; Bunyen Teng; Thomas Krahn; Stephen Tilley; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

6.  Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits.

Authors:  A el-Hashim; B D'Agostino; M G Matera; C Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

7.  Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Authors:  Philippe Van Rompaey; Kenneth A Jacobson; Ariel S Gross; Zhan-Guo Gao; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

8.  Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.

Authors:  H O Kim; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

Review 9.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release.

Authors:  Hye Sun Kuehn; Michael A Beaven; Hong-Tao Ma; Mi-Sun Kim; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2008-01-22       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.